March 27, 2020
Otsuka Pharmaceutical’s phosphodiesterase 4 (PDE4) inhibitor difamilast (OPA-15406) has demonstrated positive top-line results in two Japan PIII clinical studies in patients with atopic dermatitis, which enrolled adult and pediatric patients, respectively, the company said on March 26. The two PIII...read more